ClinicalTrials.gg
CompletedNCT01388790Updated Nov 20, 2013Results posted

Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

A Phase 2 interventional study of Cetuximab and Cisplatin in Gastric Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-11-20.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing cetuximab in Stomach Neoplasms — none open to participants now, none under way, none of them phase 3. Cetuximab · Stomach Neoplasms.

Enrollment
10th of 17
40 · median 41
Started
2011
with 1 other
Phase 2
12 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
2 of 17
Merck KGaA, Darmstadt, Germany

Among the 17 studies testing cetuximab in Stomach Neoplasms, this one is the 10th largest by enrollment, is one of 2 that started in 2011, is one of 12 in phase 2, and was the 15th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

None of the 17 studies testing cetuximab in Stomach Neoplasms is open now. The open studies under Stomach Neoplasms, anywhere →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing cetuximab in Stomach Neoplasms as a file.
02

Study summary

This open-label, single-arm, multicenter, Phase 2 trial will treat at least 40 participants with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction (GEJ) who have not previously received systemic chemotherapy for this setting.

All eligible participants will receive the combination of cetuximab plus S-1 (a combination of tegafur, gimeracil, and oteracil) and cisplatin.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Gastric Cancer
  • Cetuximab
  • EMD271786
  • TS-1
  • Cisplatin
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and agreement with medically accepted (in participants with conception potential) are obtained
  • Japanese participants aged greater than or equal to 20 years
  • confirmed adenocarcinoma of the stomach or GEJ (adenocarcinomas of the esophagogastric junction types I to III according to Siewert's classification) in Stage M0 (unresectable advanced) or Stage M1 (unresectable ) of the disease
  • Archived tumor material sample for at least subsequent standardized epidermal growth factor receptor (EGFR) expression and Kirsten-rat sarcoma (KRAS) mutation assessments
  • At least one radiographically documented in a previously non-irradiated area according to the v 1.0
  • - performance status (ECOG-PS) 0 to 1
  • Estimated greater than 12 weeks
  • Renal, liver and hematopoietic function as defined in the protocol.
  • Sodium and potassium within normal limits or as defined in the protocol
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Prior therapies: prior treatment with an antibody or molecule targeting EGFR- and/or vascular endothelial growth factor (VEGF) receptor-related signaling pathways; chemotherapies; or radiotherapies, major surgeries, and any drugs in the 30 days before the start of trial treatment
  • Concurrent chronic systemic immune or hormone therapy not indicated in this trial protocol any to treatment with cetuximab and cisplatin, or any treatments with prohibited concomitant drugs
  • and/or
  • coronary artery disease ( [NYHA] functional angina classification III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
  • Chronic diarrhea or short bowel syndrome
  • Known (HIV) infection, active or chronic carrier of virus (HBV) (HBV antigen positive or HBV deoxyribonucleic acid (DNA) positive) or virus (HCV) (HCV antibody positive)
  • Pregnancy or lactation period
  • Concurrent treatment with a non-permitted drug (any other chemotherapy, systemic anticancer therapy or immunotherapy)
  • Previous other than gastric cancer in the last 5 years Medical or psychological conditions that would not permit the participant to complete the trial or sign the Form (ICF)
  • Legal incapacity or limited legal capacity
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cetuximab plus cisplatin plus S-1

    Drug: Cetuximab · Drug: Cisplatin · Drug: S-1

Interventions

  • Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.

  • Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments

    The best overall response rate is defined as the percentage of participants having achieved confirmed complete response plus partial response as the best overall response according to radiological assessments (based on Response Evaluation Criteria in Solid Tumors version 1.0 \[RECIST v 1.0\] criteria).

    Time frame: Evaluations were performed every 6 weeks until disease progression, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012)

Secondary outcomes

  1. Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

    The PFS time is defined as the duration from start of treatment until radiological progression (based on RECIST v 1.0 criteria) or death due to any cause within 60 days of the last tumor assessment or start of treatment. Participants without event are censored on the date of last tumor assessment.

    Time frame: Time from start of treatment to disease progression, death or last tumor assessment, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012)

07

Results

Posted Nov 20, 2013

Participant flow

First/last participant (informed consent): 29 June 2011/16 January 2012; Clinical data cut-off: 14 August 2012; Study completion: 13 May 2013.

Participant flow — Overall Study
MilestoneCetuximab Plus Cisplatin Plus S-1
Started40
Completed32
Not completed8
Withdrew: Ongoing at data cut-off date8

Outcome measures

PrimaryBest Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of participants having achieved confirmed complete response plus partial response as the best overall response according to radiological assessments (based on Response Evaluation Criteria in Solid Tumors version 1.0 \[RECIST v 1.0\] criteria).

Time frame:
Evaluations were performed every 6 weeks until disease progression, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012)
Reported as:
Number · percentage of participants
Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments
percentage of participantsCetuximab Plus Cisplatin Plus S-1
Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments40 (24.9 to 56.7)
SecondaryMedian Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

The PFS time is defined as the duration from start of treatment until radiological progression (based on RECIST v 1.0 criteria) or death due to any cause within 60 days of the last tumor assessment or start of treatment. Participants without event are censored on the date of last tumor assessment.

Time frame:
Time from start of treatment to disease progression, death or last tumor assessment, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012)
Reported as:
Median · months
Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
monthsCetuximab Plus Cisplatin Plus S-1
Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments5.6 (4.2 to 8.3)

Adverse events

Collected over Time from first dose up to 30 days after the last dose of study treatment or clinical cut-off date (14 August 2012) or date of death whichever is earlier.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab Plus Cisplatin Plus S-1—15/40 (37.5%)40/40 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventCetuximab Plus Cisplatin Plus S-1
Decreased appetiteMetabolism and nutrition disorders6/40
PyrexiaGeneral disorders2/40
Acute myocardial infarctionCardiac disorders1/40
Electrocardiogram T wave inversionInvestigations1/40
Soft tissue necrosisMusculoskeletal and connective tissue disorders1/40
Renal artery thrombosisRenal and urinary disorders1/40
EmbolismVascular disorders1/40
HypotensionVascular disorders1/40
Trousseau's syndromeVascular disorders1/40
IleusGastrointestinal disorders1/40
Most frequent other events
Showing 10 of 80
Most frequent other events
EventCetuximab Plus Cisplatin Plus S-1
Dry skinSkin and subcutaneous tissue disorders30/40
StomatitisGastrointestinal disorders26/40
Decreased appetiteMetabolism and nutrition disorders26/40
ConstipationGastrointestinal disorders25/40
DiarrhoeaGastrointestinal disorders24/40
ParonychiaInfections and infestations21/40
Dermatitis acneiformSkin and subcutaneous tissue disorders21/40
NauseaGastrointestinal disorders20/40
FatigueGeneral disorders19/40
Weight decreasedInvestigations17/40

Baseline characteristics

Intent-to-treat (ITT) population included all participants who received at least one dose of study treatment.

Age Continuous
Age Continuous(years)Cetuximab Plus Cisplatin Plus S-1
Mean61.7 ± 10.09
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab Plus Cisplatin Plus S-1
Female8
Male32
08

Study locations

1 site
  • Please contact the Merck KGaA Communication Center located in
    Darmstadt, Germany
09

References and documents

Publications

  • Yamaguchi K, Fuse N, Komatsu Y, Fujii H, Hironaka S, Omuro Y, Muro K, Yasui H, Ueda S, Nishina T, Watanabe M, Ohtsu A. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. Jpn J Clin Oncol. 2021 May 28;51(6):879-885. doi: 10.1093/jjco/hyaa276. PubMed 33561262 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Aug 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2011
First posted
Jul 7, 2011
Start
Jun 2011
Primary completionActual
Aug 2012
CompletionActual
May 2013
Results first posted
Nov 20, 2013
Last update
Nov 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01388790
Responsible party
Sponsor
First posted
Jul 7, 2011
Start date
Jun 2011
Primary completion
Aug 2012
Completion
May 2013
Results posted
Nov 20, 2013
Last update
Nov 20, 2013

Study contacts

Masataka Ota, MD
study director · Merck Serono Co., Ltd., Japan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Cisplatin

Start the discussion